GW768505A free base

Cat. No.:	HY-125741
CAS No.:	501693-25-0
Molecular Formula:	$C_{27}H_{19}F_4N_5O_3$
Molecular Weight:	537.47
Target:	VEGFR; Tie
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 8.33 mg/mL (15.50 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.8606 mL	9.3028 mL	18.6057 mL
	5 mM	0.3721 mL	1.8606 mL	3.7211 mL
	10 mM	0.1861 mL	0.9303 mL	1.8606 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2, with a pIC_{50} of 7.81 for VEGFR2. GW768505A free base has anti-angiogenic activity[1].

IC_{50} & Target			
	KDR ([1])	Tie2	Tie-2

In Vitro

GW768505A free base has inhibition for cancer cells growth in NCI-60 panel screening[2].
GW768505A free base is an inhibitor of KDR and TIE2, shows potent inhibition (71–88% inhibition at 100 nM) of the tropomysin-related kinases TRKA, TRKB and TRKC[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Miyazaki Y, et al. Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2. Bioorg Med Chem Lett. 2007

Mar 15;17(6):1773-8.

[2]. Elkins JM, et al. Comprehensive characterization of the Published Kinase Inhibitor Set. Nat Biotechnol. 2016 Jan;34(1):95-103.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA